Company Filing History:
Years Active: 2024
Title: Eva De Lago: Innovator in Cannabinoid Research
Introduction
Eva De Lago is a prominent inventor based in Madrid, Spain. She has made significant contributions to the field of neurodegenerative disease treatment through her innovative research on cannabinoids. Her work focuses on the therapeutic potential of cannabinoids in addressing conditions such as amyotrophic lateral sclerosis (ALS).
Latest Patents
Eva De Lago holds a patent for the "Use of cannabinoids in the treatment of a neurodegenerative disease or disorder." This invention highlights the neuroprotective effects of cannabinoids, specifically cannabidiolic acid (CBDA) and cannabidivarin (CBDV), in a mouse model of neurodegenerative disease. The research indicates that these cannabinoids can alleviate symptoms associated with ALS. Additionally, the combination of tetrahydrocannabinol (THC) with the drug olexisome has shown a synergistic disease-modifying effect in similar models.
Career Highlights
Eva De Lago is associated with Gw Research Limited, where she continues to explore the therapeutic applications of cannabinoids. Her research has garnered attention for its potential to revolutionize treatment options for neurodegenerative diseases.
Collaborations
Eva has collaborated with notable researchers, including Benjamin Whalley and William Hind, to advance her work in cannabinoid research. Their combined expertise has contributed to the development of innovative approaches in the treatment of neurodegenerative disorders.
Conclusion
Eva De Lago's pioneering work in cannabinoid research represents a significant advancement in the treatment of neurodegenerative diseases. Her contributions have the potential to improve the quality of life for individuals affected by conditions such as ALS.